An efficient system to generate monoclonal antibodies against membrane-associated proteins by immunisation with antigen-expressing mammalian cells

Dreyer, Anita M.; Beauchamp, Jeremy; Matile, Hugues; Pluschke, Gerd
January 2010
BMC Biotechnology;2010, Vol. 10, p87
Academic Journal
Background: The generation of monoclonal antibodies specific for protein antigens usually depends on purified recombinant protein for both immunisation and hybridoma screening. Purification of recombinant protein in sufficient yield and purity is a tedious undertaking and can be demanding especially in the case of membrane proteins. Furthermore, antibodies generated against a purified recombinant protein are frequently incapable of binding to the endogenous protein in its native context. Results: We describe a strategy to generate monoclonal antibodies against membrane or membrane-associated proteins that completely bypasses any need for purified recombinant antigen. This approach utilises stably transfected mammalian cells expressing recombinant antigens on their cell surface for immunisation of mice. The transfected cells are also used for measuring seroconversion, hybridoma selection and antibody characterisation. By presenting the antigen in its native conformation for immunisation and hybridoma selection, this procedure promotes the generation of antibodies capable of binding to the endogenous protein. In the present study, we applied this approach successfully for three predicted GPI-anchored proteins of the malaria parasite Plasmodium falciparum. Conclusions: The described entirely cell-based technology is a fast and efficient approach for obtaining antibodies reactive with endogenous cell-surface proteins in their native conformation.


Related Articles

  • Structure-Guided Design of Antibodies. Caravella, Justin A.; Wang, Deping; Glaser, Scott M.; Lugovskoy, Alexey // Current Computer-Aided Drug Design;Jun2010, Vol. 6 Issue 2, p128 

    Monoclonal antibodies capable of recognizing antigens with high affinity and specificity represent a wellestablished class of biological agents. Since the development of hybridoma technology in 1975, advances in recombinant DNA technologies and computational and biophysical methods have allowed...

  • Patenting antibodies. Webber, Philip // Nature Reviews Drug Discovery;Feb2006, Vol. 5 Issue 2, p97 

    Antibody technology has advanced a long way since the early days of Kohler and Milstein's antibody-secreting murine hybridomas; and although Kohler and Milstein's invention was not patented, patent protection for the new generation of murine, chimeric, humanized and human antibody-based drugs is...

  • Modern Antibody-Based Therapeutics. Walsh, Gary // BioPharm International;Dec2004, Vol. 17 Issue 12, p18 

    The article discusses modern antibody-based therapeutics. Traditionally, polyclonal antibodies have been used to induce passive immunity. Antibody levels vary from bleed to bleed and, when the producer animal dies, so does the product source. The mid 1970s development of hybridoma technology...

  • Characterization of recombinant scFv antibody reactive with an apical antigen of Eimeria acervulina. Min, Wongi; Kim, Jin-Kyoo; Lillehoj, Hyun Soon; Sohn, Eun Jung; Han, Jae Yong; Song, Ki Duk; Lillehoj, Erik Peter // Biotechnology Letters;Jun2001, Vol. 23 Issue 12, p949 

    The chicken monoclonal antibody (mAb), 6D-12-G10, reacts with an apical complex protein at the anterior tip of E. acervulina sporozoites that inhibits parasite invasion in vitro. Because this mAb was produced at low amount from the original hybridoma cells, an scFv antibody was constructed by...

  • Production of monoclonal antibodies specific to the carboxyl terminal region of the 85 kDa subunit of phosphatidylinositol 3-kinase: Use of the antibodies in recognition of mutant p85. Daduang, Sakda; Nagata, Satoshi; Matsuda, Michiyuki; Yamori, Takao; Onodera, Kazukiyo; Fukui, Yasuhisa // Immunology & Cell Biology;Apr1995, Vol. 73 Issue 2, p134 

    We have established two hybridomas producing mAb to the carboxyl terminal region of phosphatidylinositol-3 kinase 85 kDa subunit type α (p85α). Analysis using deletion mutants of p85 revealed that epitopes for the two mAb were located on the border of the src homology 2 (SH2) sequence...

  • CHARACTERIZATION OF rBlo t 13, RECOMBINANT ALLERGEN FROM Blomia tropicalis USING MONOCLONAL ANTIBODIES. Labrada, M.; Uyema, K.; Sewer, M.; Labrada, A.; González, M.; Puerta, L.; Caraballo, L. // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    Blo t13 is a 17 kD allergen of the domestic mite Blomia tropicalis (BT), that have been cloned and expressed as a recombinant protein in E. coli and Pichia pastoris. It shows high IgE reactivity to sera of allergic patients. The biological function corresponds to fatty acid binding protein...

  • Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries. Moreland, Nicole J.; Susanto, Patricia; Lim, Elfin; Tay, Moon Y. F.; Rajamanonmani, Ravikumar; Hanson, Brendon J.; Vasudevan, Subhash G. // International Journal of Molecular Sciences;Mar2012, Vol. 13 Issue 3, p2618 

    Domain III of the dengue virus envelope protein (EDIII, aa295-395) has an immunoglobulin fold and is the proposed receptor-binding domain of the virus. Previous studies have shown that monoclonal antibodies against EDIII can be neutralizing and have therapeutic potential. Here, cloned Fab-phage...

  • Heterohybridoma for the production of non murine monoclonal antibodies. Chanu, Kh.Victoria; Ali, M. Ayub // Veterinary World;Aug2010, Vol. 3 Issue 8, p390 

    Hybridoma technology described by kohler and Milstein produce only mouse immunoglobulins. Such immunoglobulins have limited use due to its negative side effects such as the recipient's immune response. The production of a non murine monoclonal antibody to combat the problems of murine monoclonal...

  • Products of New Biotechnologies Approved by the FDA.  // Clinical Pediatrics;Apr1987, Vol. 26 Issue 4, p188 

    This article presents information related to several products manufactured by means of new biotechnology that were approved in 1986. Some of these represent major therapeutic advances while others offer important alternatives to traditional therapies. It is anticipated that there will be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics